More than Myriad: Gene Patent Discussion Must Not Forget Industrial, Environmental, Food and Agricultural Biotech
<p>
<span style="font-size: 14.3999996185303px; line-height: 24.4799995422363px;">On behalf of the 23 undersigned industrial, environmental, food and agricultural biotechnology companies, we write to express our concerns over the pending appeal in the case of Association for Molecular Pathology et al. v. Myriad Genetics et al (AMP) before the U.S. Court of Appeals for the Federal Circuit.</span></p>
On behalf of the 23 undersigned industrial, environmental, food and agricultural biotechnology companies, we write to express our concerns over the pending appeal in the case of Association for Molecular Pathology et al. v. Myriad Genetics et al (AMP) before the U.S. Court of Appeals for the Federal Circuit. We feel it is essential that it be understood that this case could potentially adversely impact ours and other industries whose activities are far removed from the clinical diagnostic testing context in which this case is commonly discussed.
